Serglycin expression in CD2+ and CD14+ cells from patients with various rheumatic diseases.
The objective of the study was to look at the in vivo expression of serglycin in cells taken from patients with an inflammatory disease. The mRNA expression of the small proteoglycan serglycin was investigated in macrophages/monocytes and T-cells derived from the synovial fluid and blood of six patients with various rheumatic diseases and from the blood of two control subjects. Our results demonstrate higher Levels of expression in CD14+ cetts taken from patients with chronic inflammatory diseases than in control subjects. This suggests that serglycin may play a role during the inflammatory process.
Omtvedt
L A
LA
Centre for Rheumatic Diseases, The National Hospital, University of Oslo, Norway.
Kolset
S O
SO
Thoen
J
J
Førre
Y
Y
Gill
M R
MR
D000328:Adult; D000368:Aged; D018801:CD2 Antigens / Q000032:analysis; D005260:Female; D006801:Humans; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D016131:Lymphocyte Subsets / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011509:Proteoglycans / Q000097:blood* / Q000378:metabolism; D012216:Rheumatic Diseases / Q000097:blood* / Q000378:metabolism; D013582:Synovial Fluid / Q000378:metabolism*; D033921:Vesicular Transport Proteins
D018801:CD2 Antigens; D018950:Lipopolysaccharide Receptors; D011509:Proteoglycans; D033921:Vesicular Transport Proteins; C075430:serglycin